BMS' SECOND ACE: MONOPRIL WILL BE DETAILED BY OVER 1,300 REPS under a copromotion effort by Boehringer Ingelheim and Bristol- Myers Squibb's Mead Johnson and Hospital and Institutional Products Divisions. Monopril (fosinopril) was approved for treatment of hypertension May 16. The second generation angiotensin-converting enzyme inhibitor received a "IC" rating from FDA (new molecular entity with little or no therapeutic advantage over existing products). Squibb filed the fosinopril NDA on Nov. 15, 1988. Bristol-Myers Squibb said it has yet to set a launch date. Monopril is the fifth ACE inhibitor approved by FDA and the third once-a-day product. Squibb's Capoten (captopril), approved in 1981, was the first. Capoten was followed by Merck's Vasotec (enalapril) and Prinivil (lisinopril), the first once-a-day ACE inhibitor, and Hoechst-Roussel's Altace (ramipril), which was approved on Jan. 29 as the second once-daily product. ICI comarkets lisinopril under the tradename Zestril. Like Merck, Bristol-Myers Squibb has a partner for its second ACE inhibitor: under a 1988 deal with Squibb, Boehringer Ingelheim will copromote Monopril ("The Pink Sheet" Jan. 11, 1988, T&G-1). The two companies will promote the product with a total of 1,344 reps: 667 from BMS' Mead Johnson Division, 463 from Boehringer Ingelheim, and 214 from BMS' Hospital and Institutional Products Division, the company said. Monopril 10 mg once-a-day is indicated "for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics," approved labeling states. The indication statement carries a warning that FDA has required all ACE inhibitors to carry: "consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particulary in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that Monopril does not have a similar risk." Monopril's other warning statements and information for patients are also typical of the ACE class: in addition to agranulocytosis/neutropenia, the label warns of the possibility of angiodema, hypotension, renal impairment and hyperkalemia. Labeling includes an additional precaution against the possibility of liver impairment, since "fosinopril is mainly metabolized by hepatic and gut wall esterases." A Bristol-Myers Squibb press release characterizes the "dual elimination" of Monopril by the liver and the kidneys as a feature distinguishing its product: "most marketed ACE inhibitors are eliminated primarily by the kidneys," the release states. "The dual elimination profile of Monopril may prove beneficial to a broad range of patients, especially to older hypertensive patients, since kidney function may decline both with age and as a result of hypertension." BMS stressed Monopril's efficacy in geriatric populations. The label notes that 13% of the over 1,600 patients involved in clinical trials with Monopril were 65 or older. "No overall difference in safety and efficacy" was seen in the elderly, labeling states, although "greater sensitivity of some older individuals cannot be ruled out."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.
Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.
